<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>375</ReferenceId>
        <DateLastUpdated>2011-03-28-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15538043</PubmedId>
            <Abstract>A breast cancer-associated antigen, mammaglobin-A, is specifically expressed in 80% of primary breast tumors. The definition of immune responses against this highly expressed breast cancer-specific antigen should be of great value in the development of new therapeutic strategies for breast cancer. Thus, the purpose of this study was to identify HLA-A2-restricted mammaglobin-A-derived epitopes recognized by CD8+ cytotoxic T lymphocytes (CTL). We identified seven mammaglobin-A-derived candidate epitopes that bind the HLA-A2 molecule (Mam-A2.1-7) by means of a HLA class I-peptide binding computer algorithm from the Bioinformatics &amp; Molecular Analysis Section of the National Institutes of Health. Subsequently, we determined that CD8+ CTLs from breast cancer patients reacted to the Mam-A2.1 (83-92, LIYDSSLCDL), Mam-A2.2 (2-10, KLLMVLMLA), Mam-A2.3 (4-12, LMVLMLAAL), Mam-A2.4 (66-74, FLNQTDETL), and Mam-A2.7 (32-40, TINPQVSKT) epitopes using an IFN-gamma ELISPOT assay. Interestingly, healthy individuals also showed high reactivity to the Mam-A2.2 epitope. Two CD8+ CTL lines generated in vitro against TAP-deficient T2 cells loaded with the candidate epitopes showed significant cytotoxic activity against the Mam-A2.1-4 epitopes. These CD8+CTL lines recognized a HLA-A2+breast cancer cell line expressing the Mam-A2.1 epitope. In addition, DNA vaccination of HLA-A2+/human CD8+ double-transgenic mice with a DNA construct encoding the Mam-A2.1 epitope and the HLA-A2 molecule induced a significant expansion of epitope-specific CD8+ CTLs that recognize the same HLA- A2+/Mam-A2.1+ breast cancer cell line. In conclusion, these results demonstrate the immunotherapeutic potential of mammaglobin-A for the treatment and prevention of breast cancer.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>29-41</ArticlePages>
            <ArticleTitle>Recognition of HLA-A2-restricted mammaglobin-A-derived epitopes by CD8+ cytotoxic T lymphocytes from breast cancer patients.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Jaramillo</LastName>
                    <ForeName>André</ForeName>
                </Author>
                <Author>
                    <LastName>Narayanan</LastName>
                    <ForeName>Kishore</ForeName>
                </Author>
                <Author>
                    <LastName>Campbell</LastName>
                    <ForeName>Lacey G</ForeName>
                </Author>
                <Author>
                    <LastName>Benshoff</LastName>
                    <ForeName>Nicholas D</ForeName>
                </Author>
                <Author>
                    <LastName>Lybarger</LastName>
                    <ForeName>Lonnie</ForeName>
                </Author>
                <Author>
                    <LastName>Hansen</LastName>
                    <ForeName>Ted H</ForeName>
                </Author>
                <Author>
                    <LastName>Fleming</LastName>
                    <ForeName>Timothy P</ForeName>
                </Author>
                <Author>
                    <LastName>Dietz</LastName>
                    <ForeName>Jill R</ForeName>
                </Author>
                <Author>
                    <LastName>Mohanakumar</LastName>
                    <ForeName>T</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA. jaramilloa@wustl.edu</Affiliations>
            <ArticleChemicalList>Antigens, Neoplasm;Epitopes;HLA-A2 Antigen;Neoplasm Proteins;Vaccines, DNA;mammaglobin;Uteroglobin</ArticleChemicalList>
            <ArticleMeshHeadingsList>Adenocarcinoma(immunology; pathology ); Animals; Antigens, Neoplasm; Breast Neoplasms(immunology; pathology ); Epitopes; Female; HLA-A2 Antigen(analysis ); Humans; Immunotherapy(methods ); Mice; Mice, Transgenic; Neoplasm Proteins(analysis; immunology ); Neoplasms, Experimental; Research Support, Non-U.S. Gov't; T-Lymphocytes, Cytotoxic(immunology ); Tumor Cells, Cultured; Uteroglobin(analysis; immunology ); Vaccines, DNA </ArticleMeshHeadingsList>
            <Journal>
                <Volume>88</Volume>
                <Issue>1</Issue>
                <Title>Breast cancer research and treatment</Title>
                <Issn>0167-6806</Issn>
                <MedlineTa>Breast Cancer Res Treat</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>Mam-A2.1</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LIYDSSLCDL</LinearSequence>
                        <StartingPosition>83</StartingPosition>
                        <EndingPosition>92</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>2833243</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 2</LocationOfData>
                <EpitopeId>36773</EpitopeId>
                <ReferenceStartingPosition>83</ReferenceStartingPosition>
                <ReferenceEndingPosition>92</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <TCellId>940</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>No immunization</InVivoProcessType>
                                <DiseaseState>DTREE_00000014</DiseaseState>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Primary induction in vitro</ProcessType>
                                <ResponderCellType>T cell CD8+</ResponderCellType>
                                <StimulatorCellType>T2 cells-Lymphoblast</StimulatorCellType>
                                <ImmunogenReferenceName>Mam-A2.1</ImmunogenReferenceName>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>LIYDSSLCDL</LinearSequence>
                                            <StartingPosition>83</StartingPosition>
                                            <EndingPosition>92</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>2833243</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Peripheral blood lymphocytes were cultured with peptide-loaded T2 cells, treated with CD28.2 anti-CD28 mAb, recombinant human IL-2 and restimulated every 8-10 days three times with peptide-loaded T2 cells and autologous peripheral blood lymphocytes.  Then CD8+ CTLs were purified by negative selection with anti-CD4-coated microbeads, and further purified to include only CD3+ cells. These cells were &gt;95% CD8+ by flow cytometric analysis.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Breast</CellTissueType>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>mammaglobin-A</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>2833243</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>135</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Lysis of the UACC-812 breast cancer cell line was blocked by the addition of 20-fold excess of T2 cells loaded with Mam-A2.1 peptide, whereas T2 cells loaded with Mam-A2.2, 2.3, and 2.4 peptides had no effect on cytotoxicity activity against the UACC-812 breast cancer cell line. HLA-A2-restriction was confirmed by the anti-HLA-A2 monoclonal antibody effectively  blocking lysis.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 6B</LocationOfData>
                        <TCellId>1770</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000075</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>LIYDSSLCDL</LinearSequence>
                                            <StartingPosition>83</StartingPosition>
                                            <EndingPosition>92</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>2833243</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Mam-A2.1-β&lt;sub&gt;2&lt;/sub&gt;m-HLA-A2</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>Four times, two weeks apart.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The DNA construct encoded the leader sequence of murine β-m followed by the Mam-A2.1 peptide sequence, then a linker of 10-15 residues ((G4S)2-3), followed by the murine β-m sequence, a second linker of 15-20 residues ((G4S)3-4) and the HLA-A2 α chain sequence.  The construct was expressed using the pIRES.neo vector from Clontech.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Breast</CellTissueType>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>143</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Mammaglobin-A</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>2833243</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The breast cancer cell line UACC-812 (HLA-A2+ and mammaglobin-A+) was used as target cells with positive results.  Other breast cancer cell lines that were either HLA-A2- or mammaglobin-A- did not yield significant lysis.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 3</LocationOfData>
                        <TCellId>558</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:1612</DiseaseState>
                                <DiseaseStage>Unknown</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>2833243</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>mammaglobin-A</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Mam-A2.1</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LIYDSSLCDL</LinearSequence>
                                        <StartingPosition>83</StartingPosition>
                                        <EndingPosition>92</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>2833243</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>8</NumberOfSubjectsTested>
                            <AssayComments>5 out of 8 (62.5%) breast cancer patients showed CD8+ CTL reactivity against peptide Mam-A2.1 (P&lt;0.01student t-test).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>559</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>No immunization</InVivoProcessType>
                                <DiseaseState>DTREE_00000014</DiseaseState>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Primary induction in vitro</ProcessType>
                                <ResponderCellType>T cell CD8+</ResponderCellType>
                                <StimulatorCellType>T2 cells-Lymphoblast</StimulatorCellType>
                                <ImmunogenReferenceName>Mam-A2.1</ImmunogenReferenceName>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>LIYDSSLCDL</LinearSequence>
                                            <StartingPosition>83</StartingPosition>
                                            <EndingPosition>92</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>2833243</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>CD8+ T cell lines were generated by in vitro stimulations with pooled T2 cells individually loaded with peptides.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Mam-A2.1</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LIYDSSLCDL</LinearSequence>
                                        <StartingPosition>83</StartingPosition>
                                        <EndingPosition>92</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>2833243</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Immunodominance was evaluated in CD8+ cell lines from healthy subjects using T2 cells individually loaded with peptides. In another cytotoxicity assay,  the same CD8+ cell lines were used with nine different breast cancer cell lines to evaluate the mammaglobin-A-specificity and HLA-A2-restriction of the CD8+ CTL lines.  A strong response was given by breast cancer cell line UACC-812, which is HLA-A2+ and mammaglobin-A+, but no cytotoxic activity was seen with two other breast cancer cell lines, HBL-100, and AU-565, both of which are also HLA-A2+ and Mammaglobin-A+.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 6A</LocationOfData>
                        <TCellId>1983</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000075</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>LIYDSSLCDL</LinearSequence>
                                            <StartingPosition>83</StartingPosition>
                                            <EndingPosition>92</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>2833243</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Mam-A2.1-β&lt;sub&gt;2&lt;/sub&gt;m-HLA-A2</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intramuscular</Route>
                                <DoseSchedule>Four times, 2 weeks apart.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The DNA construct encoded the leader sequence of murine β-m followed by the Mam-A2.1 peptide sequence, then a linker of 10-15 residues ((G4S)2-3), followed by the murine β-m sequence, a second linker of 15-20 residues ((G4S)3-4) and the HLA-A2 α chain sequence.  The construct was expressed using the pIRES.neo vector from Clontech.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>143</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Mam-A2.1</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LIYDSSLCDL</LinearSequence>
                                        <StartingPosition>83</StartingPosition>
                                        <EndingPosition>92</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>2833243</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 1</LocationOfData>
                        <MhcBindingId>556</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>185</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The HLA-A2-binding ability of the epitope was predicted by computer algorithm and confirmed by membrane stabilization of the HLA-A2 molecule in T2 cells.  Flow cytometry with BB7.2 anti HLA-A2 mAb was used to determine the levels of HLA-A2 expression.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>235</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Mam-A2.2</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>KLLMVLMLA</LinearSequence>
                        <StartingPosition>2</StartingPosition>
                        <EndingPosition>10</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>2833243</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 2</LocationOfData>
                <EpitopeId>31987</EpitopeId>
                <ReferenceStartingPosition>2</ReferenceStartingPosition>
                <ReferenceEndingPosition>10</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 3</LocationOfData>
                        <TCellId>7334</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:1612</DiseaseState>
                                <DiseaseStage>Unknown</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>2833243</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>mammaglobin-A</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Mam-A2.2</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KLLMVLMLA</LinearSequence>
                                        <StartingPosition>2</StartingPosition>
                                        <EndingPosition>10</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>2833243</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>8</NumberOfSubjectsTested>
                            <AssayComments>6 out of 8 (75%) breast cancer patients showed CD8+ CTL reactivity against peptide Mam-A2.2 (P&lt;0.01student t-test).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>7335</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>No immunization</InVivoProcessType>
                                <DiseaseState>DTREE_00000014</DiseaseState>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Primary induction in vitro</ProcessType>
                                <ResponderCellType>T cell CD8+</ResponderCellType>
                                <StimulatorCellType>T2 cells-Lymphoblast</StimulatorCellType>
                                <ImmunogenReferenceName>Mam-A2.2</ImmunogenReferenceName>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>KLLMVLMLA</LinearSequence>
                                            <StartingPosition>2</StartingPosition>
                                            <EndingPosition>10</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>2833243</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>CD8+ T cell lines were generated by in vitro stimulations with pooled T2 cells individually loaded with peptides.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Mam-A2.2</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>KLLMVLMLA</LinearSequence>
                                        <StartingPosition>2</StartingPosition>
                                        <EndingPosition>10</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>2833243</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Immunodominance was evaluated in CD8+ cell lines from healthy subjects using T2 cells individually loaded with peptides. In another cytotoxicity assay,  the same CD8+ cell lines were used with nine different breast cancer cell lines to evaluate the mammaglobin-A-specificity and HLA-A2-restriction of the CD8+ CTL lines.  A strong response was given by breast cancer cell line UACC-812, which is HLA-A2+ and mammaglobin-A+, but no cytotoxic activity was seen with two other breast cancer cell lines, HBL-100, and AU-565, both of which are also HLA-A2+ and Mammaglobin-A+.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <TCellId>7336</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>No immunization</InVivoProcessType>
                                <DiseaseState>DTREE_00000014</DiseaseState>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Primary induction in vitro</ProcessType>
                                <ResponderCellType>T cell CD8+</ResponderCellType>
                                <StimulatorCellType>T2 cells-Lymphoblast</StimulatorCellType>
                                <ImmunogenReferenceName>Mam-A2.2</ImmunogenReferenceName>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>KLLMVLMLA</LinearSequence>
                                            <StartingPosition>2</StartingPosition>
                                            <EndingPosition>10</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>2833243</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Peripheral blood lymphocytes were cultured with peptide-loaded T2 cells, treated with CD28.2 anti-CD28 mAb, recombinant human IL-2 and restimulated every 8-10 days three times with peptide-loaded T2 cells and autologous peripheral blood lymphocytes.  Then CD8+ CTLs were purified by negative selection with anti-CD4-coated microbeads, and further purified to include only CD3+ cells. These cells were &gt;95% CD8+ by flow cytometric analysis.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Breast</CellTissueType>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>mammaglobin-A</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>2833243</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>135</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Lysis of the UACC-812 breast cancer cell line was blocked by the addition of 20-fold excess of T2 cells loaded with Mam-A2.1 peptide, whereas T2 cells loaded with Mam-A2.2, 2.3, and 2.4 peptides had no effect on cytotoxicity activity against the UACC-812 breast cancer cell line. HLA-A2-restriction was confirmed by the anti-HLA-A2 monoclonal antibody effectively  blocking lysis.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 1</LocationOfData>
                        <MhcBindingId>7333</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>185</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The HLA-A2-binding ability of the epitope was predicted by computer algorithm and confirmed by membrane stabilization of the HLA-A2 molecule in T2 cells.  Flow cytometry with BB7.2 anti HLA-A2 mAb was used to determine the levels of HLA-A2 expression.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>235</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Mam-A2.3</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LMVLMLAAL</LinearSequence>
                        <StartingPosition>4</StartingPosition>
                        <EndingPosition>12</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>2833243</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 2</LocationOfData>
                <EpitopeId>38148</EpitopeId>
                <ReferenceStartingPosition>4</ReferenceStartingPosition>
                <ReferenceEndingPosition>12</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>7341</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>No immunization</InVivoProcessType>
                                <DiseaseState>DTREE_00000014</DiseaseState>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Primary induction in vitro</ProcessType>
                                <ResponderCellType>T cell CD8+</ResponderCellType>
                                <StimulatorCellType>T2 cells-Lymphoblast</StimulatorCellType>
                                <ImmunogenReferenceName>Mam-A2.3</ImmunogenReferenceName>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>LMVLMLAAL</LinearSequence>
                                            <StartingPosition>4</StartingPosition>
                                            <EndingPosition>12</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>2833243</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>CD8+ T cell lines were generated by in vitro stimulations with pooled T2 cells individually loaded with peptides.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Mam-A2.3</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LMVLMLAAL</LinearSequence>
                                        <StartingPosition>4</StartingPosition>
                                        <EndingPosition>12</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>2833243</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Immunodominance was evaluated in CD8+ cell lines from healthy subjects using T2 cells individually loaded with peptides. In another cytotoxicity assay,  the same CD8+ cell lines were used with nine different breast cancer cell lines to evaluate the mammaglobin-A-specificity and HLA-A2-restriction of the CD8+ CTL lines.  A strong response was given by breast cancer cell line UACC-812, which is HLA-A2+ and mammaglobin-A+, but no cytotoxic activity was seen with two other breast cancer cell lines, HBL-100, and AU-565, both of which are also HLA-A2+ and Mammaglobin-A+.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <TCellId>7342</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>No immunization</InVivoProcessType>
                                <DiseaseState>DTREE_00000014</DiseaseState>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Primary induction in vitro</ProcessType>
                                <ResponderCellType>T cell CD8+</ResponderCellType>
                                <StimulatorCellType>T2 cells-Lymphoblast</StimulatorCellType>
                                <ImmunogenReferenceName>Mam-A2.3</ImmunogenReferenceName>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>LMVLMLAAL</LinearSequence>
                                            <StartingPosition>4</StartingPosition>
                                            <EndingPosition>12</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>2833243</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Peripheral blood lymphocytes were cultured with peptide-loaded T2 cells, treated with CD28.2 anti-CD28 mAb, recombinant human IL-2 and restimulated every 8-10 days three times with peptide-loaded T2 cells and autologous peripheral blood lymphocytes.  Then CD8+ CTLs were purified by negative selection with anti-CD4-coated microbeads, and further purified to include only CD3+ cells. These cells were &gt;95% CD8+ by flow cytometric analysis.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Breast</CellTissueType>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>mammaglobin-A</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>2833243</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>135</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Lysis of the UACC-812 breast cancer cell line was blocked by the addition of 20-fold excess of T2 cells loaded with Mam-A2.1 peptide, whereas T2 cells loaded with Mam-A2.2, 2.3, and 2.4 peptides had no effect on cytotoxicity activity against the UACC-812 breast cancer cell line. HLA-A2-restriction was confirmed by the anti-HLA-A2 monoclonal antibody effectively  blocking lysis.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 3</LocationOfData>
                        <TCellId>7340</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:1612</DiseaseState>
                                <DiseaseStage>Unknown</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>2833243</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>mammaglobin-A</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Mam-A2.3</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LMVLMLAAL</LinearSequence>
                                        <StartingPosition>4</StartingPosition>
                                        <EndingPosition>12</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>2833243</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>8</NumberOfSubjectsTested>
                            <AssayComments>5 out of 8 (62.5%) breast cancer patients showed CD8+ CTL reactivity against peptide Mam-A2.3 (P&lt;0.01student t-test).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 1</LocationOfData>
                        <MhcBindingId>7339</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>185</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The HLA-A2-binding ability of the epitope was predicted by computer algorithm and confirmed by membrane stabilization of the HLA-A2 molecule in T2 cells.  Flow cytometry with BB7.2 anti HLA-A2 mAb was used to determine the levels of HLA-A2 expression.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>235</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Mam-A2.4</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FLNQTDETL</LinearSequence>
                        <StartingPosition>66</StartingPosition>
                        <EndingPosition>74</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>2833243</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 2</LocationOfData>
                <EpitopeId>16785</EpitopeId>
                <ReferenceStartingPosition>66</ReferenceStartingPosition>
                <ReferenceEndingPosition>74</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 4</LocationOfData>
                        <TCellId>7346</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>No immunization</InVivoProcessType>
                                <DiseaseState>DTREE_00000014</DiseaseState>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Primary induction in vitro</ProcessType>
                                <ResponderCellType>T cell CD8+</ResponderCellType>
                                <StimulatorCellType>T2 cells-Lymphoblast</StimulatorCellType>
                                <ImmunogenReferenceName>Mam-A2.4</ImmunogenReferenceName>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>FLNQTDETL</LinearSequence>
                                            <StartingPosition>66</StartingPosition>
                                            <EndingPosition>74</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>2833243</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Peripheral blood lymphocytes were cultured with peptide-loaded T2 cells, treated with CD28.2 anti-CD28 mAb, recombinant human IL-2 and restimulated every 8-10 days three times with peptide-loaded T2 cells and autologous peripheral blood lymphocytes.  Then CD8+ CTLs were purified by negative selection with anti-CD4-coated microbeads, and further purified to include only CD3+ cells. These cells were &gt;95% CD8+ by flow cytometric analysis.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Breast</CellTissueType>
                            <CellType>Other</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>mammaglobin-A</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>2833243</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>135</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Lysis of the UACC-812 breast cancer cell line was blocked by the addition of 20-fold excess of T2 cells loaded with Mam-A2.1 peptide, whereas T2 cells loaded with Mam-A2.2, 2.3, and 2.4 peptides had no effect on cytotoxicity activity against the UACC-812 breast cancer cell line. HLA-A2-restriction was confirmed by the anti-HLA-A2 monoclonal antibody effectively  blocking lysis.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 3</LocationOfData>
                        <TCellId>7344</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:1612</DiseaseState>
                                <DiseaseStage>Unknown</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>2833243</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>mammaglobin-A</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Mam-A2.4</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FLNQTDETL</LinearSequence>
                                        <StartingPosition>66</StartingPosition>
                                        <EndingPosition>74</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>2833243</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>8</NumberOfSubjectsTested>
                            <AssayComments>4 out of 8 (50%) breast cancer patients showed CD8+ CTL reactivity against peptide Mam-A2.4 (P&lt;0.01student t-test).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>7345</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>No immunization</InVivoProcessType>
                                <DiseaseState>DTREE_00000014</DiseaseState>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Primary induction in vitro</ProcessType>
                                <ResponderCellType>T cell CD8+</ResponderCellType>
                                <StimulatorCellType>T2 cells-Lymphoblast</StimulatorCellType>
                                <ImmunogenReferenceName>Mam-A2.4</ImmunogenReferenceName>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>FLNQTDETL</LinearSequence>
                                            <StartingPosition>66</StartingPosition>
                                            <EndingPosition>74</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>2833243</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>CD8+ T cell lines were generated by in vitro stimulations with pooled T2 cells individually loaded with peptides.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Mam-A2.4</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FLNQTDETL</LinearSequence>
                                        <StartingPosition>66</StartingPosition>
                                        <EndingPosition>74</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>2833243</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>Immunodominance was evaluated in CD8+ cell lines from healthy subjects using T2 cells individually loaded with peptides. In another cytotoxicity assay,  the same CD8+ cell lines were used with nine different breast cancer cell lines to evaluate the mammaglobin-A-specificity and HLA-A2-restriction of the CD8+ CTL lines.  A strong response was given by the breast cancer cell line UACC-812, which is HLA-A2+ and mammaglobin-A+, but no cytotoxic activity was seen with two other breast cancer cell lines, HBL-100, and AU-565, both of which are also HLA-A2+ and Mammaglobin-A+.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 1</LocationOfData>
                        <MhcBindingId>7343</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>185</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The HLA-A2-binding ability of the epitope was predicted by computer algorithm and confirmed by membrane stabilization of the HLA-A2 molecule in T2 cells.  Flow cytometry with BB7.2 anti HLA-A2 mAb was used to determine the levels of HLA-A2 expression.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>235</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Mam-A2.5</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TLSNVEVFM</LinearSequence>
                        <StartingPosition>73</StartingPosition>
                        <EndingPosition>81</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>2833243</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 2</LocationOfData>
                <EpitopeId>65064</EpitopeId>
                <ReferenceStartingPosition>73</ReferenceStartingPosition>
                <ReferenceEndingPosition>81</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 3</LocationOfData>
                        <TCellId>7348</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:1612</DiseaseState>
                                <DiseaseStage>Unknown</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>2833243</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>mammaglobin-A</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Mam-A2.5</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TLSNVEVFM</LinearSequence>
                                        <StartingPosition>73</StartingPosition>
                                        <EndingPosition>81</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>2833243</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>8</NumberOfSubjectsTested>
                            <AssayComments>0 out of 8 breast cancer patients showed CD8+ CTL reactivity against peptide Mam-A2.5 (P&lt;0.01student t-test).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>7349</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>No immunization</InVivoProcessType>
                                <DiseaseState>DTREE_00000014</DiseaseState>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Primary induction in vitro</ProcessType>
                                <ResponderCellType>T cell CD8+</ResponderCellType>
                                <StimulatorCellType>T2 cells-Lymphoblast</StimulatorCellType>
                                <ImmunogenReferenceName>Mam-A2.5</ImmunogenReferenceName>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>TLSNVEVFM</LinearSequence>
                                            <StartingPosition>73</StartingPosition>
                                            <EndingPosition>81</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>2833243</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>CD8+ T cell lines were generated by in vitro stimulations with pooled T2 cells individually loaded with peptides.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Mam-A2.5</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TLSNVEVFM</LinearSequence>
                                        <StartingPosition>73</StartingPosition>
                                        <EndingPosition>81</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>2833243</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Immunodominance was evaluated in CD8+ cell lines from healthy subjects using T2 cells individually loaded with peptides. In another cytotoxicity assay,  the same CD8+ cell lines were used with nine different breast cancer cell lines to evaluate the mammaglobin-A-specificity and HLA-A2-restriction of the CD8+ CTL lines.  A strong response was given by breast cancer cell line UACC-812, which is HLA-A2+ and mammaglobin-A+, but no cytotoxic activity was seen with two other breast cancer cell lines, HBL-100, and AU-565, both of which are also HLA-A2+ and Mammaglobin-A+.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 1</LocationOfData>
                        <MhcBindingId>7347</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>185</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The HLA-A2-binding ability of the test epitope was predicted by computer algorithm and confirmed by membrane stabilization of the HLA-A2 molecule in T2 cells.  Flow cytometry with BB7.2 anti HLA-A2 mAb was used to determine the levels of HLA-A2 expression.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>235</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Mam-A2.6</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>MQLIYDSSL</LinearSequence>
                        <StartingPosition>81</StartingPosition>
                        <EndingPosition>89</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>2833243</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 2</LocationOfData>
                <EpitopeId>42387</EpitopeId>
                <ReferenceStartingPosition>81</ReferenceStartingPosition>
                <ReferenceEndingPosition>89</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 3</LocationOfData>
                        <TCellId>7352</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:1612</DiseaseState>
                                <DiseaseStage>Unknown</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>2833243</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>mammaglobin-A</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Mam-A2.6</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MQLIYDSSL</LinearSequence>
                                        <StartingPosition>81</StartingPosition>
                                        <EndingPosition>89</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>2833243</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <NumberOfSubjectsTested>8</NumberOfSubjectsTested>
                            <AssayComments>0 out of 8 breast cancer patients showed CD8+ CTL reactivity against peptide Mam-A2.6 (P&lt;0.01student t-test).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 2</LocationOfData>
                        <TCellId>7353</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>No immunization</InVivoProcessType>
                                <DiseaseState>DTREE_00000014</DiseaseState>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Primary induction in vitro</ProcessType>
                                <ResponderCellType>T cell CD8+</ResponderCellType>
                                <StimulatorCellType>T2 cells-Lymphoblast</StimulatorCellType>
                                <ImmunogenReferenceName>Mam-A2.6</ImmunogenReferenceName>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>MQLIYDSSL</LinearSequence>
                                            <StartingPosition>81</StartingPosition>
                                            <EndingPosition>89</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>2833243</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>CD8+ T cell lines were generated by in vitro stimulations with pooled T2 cells individually loaded with peptides.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Mam-A2.6</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MQLIYDSSL</LinearSequence>
                                        <StartingPosition>81</StartingPosition>
                                        <EndingPosition>89</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>2833243</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Immunodominance was evaluated in CD8+ cell lines from healthy subjects using T2 cells individually loaded with peptides. In another cytotoxicity assay,  the same CD8+ cell lines were used with nine different breast cancer cell lines to evaluate the mammaglobin-A-specificity and HLA-A2-restriction of the CD8+ CTL lines.  A strong response was given by the breast cancer cell line UACC-812, which is HLA-A2+ and mammaglobin-A+, but no cytotoxic activity was seen with two other breast cancer cell lines, HBL-100, and AU-565, both of which are also HLA-A2+ and Mammaglobin-A+.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 1</LocationOfData>
                        <MhcBindingId>7351</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>185</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The HLA-A2-binding ability of the test epitope was predicted by computer algorithm and confirmed by membrane stabilization of the HLA-A2 molecule in T2 cells.  Flow cytometry with BB7.2 anti HLA-A2 mAb was used to determine the levels of HLA-A2 expression.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>235</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>Mam-A2.7</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>TINPQVSKT</LinearSequence>
                        <StartingPosition>32</StartingPosition>
                        <EndingPosition>40</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>2833243</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 2</LocationOfData>
                <EpitopeId>64399</EpitopeId>
                <ReferenceStartingPosition>32</ReferenceStartingPosition>
                <ReferenceEndingPosition>40</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Fig. 2</LocationOfData>
                        <TCellId>7356</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>No immunization</InVivoProcessType>
                                <DiseaseState>DTREE_00000014</DiseaseState>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Primary induction in vitro</ProcessType>
                                <ResponderCellType>T cell CD8+</ResponderCellType>
                                <StimulatorCellType>T2 cells-Lymphoblast</StimulatorCellType>
                                <ImmunogenReferenceName>Mam-A2.7</ImmunogenReferenceName>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>TINPQVSKT</LinearSequence>
                                            <StartingPosition>32</StartingPosition>
                                            <EndingPosition>40</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>2833243</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>CD8+ T cell lines were generated by in vitro stimulations with pooled T2 cells individually loaded with peptides.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Lymphoid</CellTissueType>
                            <CellType>T2 cells-Lymphoblast</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                            <SourceOrganismId>9606</SourceOrganismId>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Mam-A2.7</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TINPQVSKT</LinearSequence>
                                        <StartingPosition>32</StartingPosition>
                                        <EndingPosition>40</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>2833243</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>Immunodominance was evaluated in CD8+ cell lines from healthy subjects using T2 cells individually loaded with peptides. In another cytotoxicity assay,  the same CD8+ cell lines were used with nine different breast cancer cell lines to evaluate the mammaglobin-A-specificity and HLA-A2-restriction of the CD8+ CTL lines.  A strong response was given by the breast cancer cell line UACC-812, which is HLA-A2+ and mammaglobin-A+, but no cytotoxic activity was seen with two other breast cancer cell lines, HBL-100, and AU-565, both of which are also HLA-A2+ and Mammaglobin-A+.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 3</LocationOfData>
                        <TCellId>7355</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>9606</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Occurrence of cancer</InVivoProcessType>
                                <DiseaseState>DOID:1612</DiseaseState>
                                <DiseaseStage>Unknown</DiseaseStage>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>2833243</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>mammaglobin-A</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                            </FirstInVivoProcess>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Blood</CellTissueType>
                            <CellType>PBMC</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Mam-A2.7</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TINPQVSKT</LinearSequence>
                                        <StartingPosition>32</StartingPosition>
                                        <EndingPosition>40</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>2833243</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Not determined</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>8</NumberOfSubjectsTested>
                            <AssayComments>5 out of 8 (62.5%) breast cancer patients showed CD8+ CTL reactivity against peptide Mam-A2.7.  (P&lt;0.01student t-test).</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <MhcBinding>
                        <LocationOfData>Figure 1</LocationOfData>
                        <MhcBindingId>7354</MhcBindingId>
                        <AssayInformation>
                            <AssayTypeId>185</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The HLA-A2-binding ability of the epitope was predicted by computer algorithm and confirmed by membrane stabilization of the HLA-A2 molecule in T2 cells.  Flow cytometry with BB7.2 anti HLA-A2 mAb was used to determine the levels of HLA-A2 expression.</AssayComments>
                        </AssayInformation>
                        <MhcAlleleId>235</MhcAlleleId>
                    </MhcBinding>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

